GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

Ischemic stroke market Insights: Rising prevalence of ischemic strokes boosts demand for effective treatment and prevention strategies.

MUMBAI: Kedaara Capital  is laying it on  thick with advisors. The latest to be added on its roster is Jai Shankar Krishnan as an operating advisor, effective immediately.  With over three decades of ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

GSK PLC GSK shares inched down 0.37% to £13.54 Monday, on what proved to be an all-around favorable trading session for the ...

European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

The global effervescent tablet market size is estimated to grow by USD 4.80 billion from 2024 to 2028, according to Technavio ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...